Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients
Claudia Alteri, Valeria Fox, Rossana Scutari, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 22

Showing 22 citing articles:

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, et al.
Nature (2023) Vol. 623, Iss. 7987, pp. 594-600
Open Access | Times Cited: 114
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 16
Analysis of SARS-CoV-2 genome evolutionary patterns
Shubhangi Gupta, Deepanshu Gupta, Sonika Bhatnagar
Microbiology Spectrum (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 6
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody
Shuhei Maruyama, Daiki Wada, Shuji Kanayama, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Molnupiravir: From Hope to Epic Fail?
Daniele Focosi
Viruses (2022) Vol. 14, Iss. 11, pp. 2560-2560
Open Access | Times Cited: 25
Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection
Christopher J. R. Illingworth, José Afonso Guerra‐Assunção, Samuel Gregg, et al.
Virus Evolution (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 4
N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
Arne Zibat, Xiaoxiao Zhang, Antje Dickmanns, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107786-107786
Open Access | Times Cited: 10
Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study
Cesare Ernesto Maria Gruber, Fabio Giovanni Tucci, Emanuela Giombini, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 5
Open Access | Times Cited: 2
Analysis of spike protein variants evolved in a novel in vivo long-term replication model for SARS-CoV-2
Dongbum Kim, Jin-Soo Kim, Minyoung Kim, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 6
Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study
Haruka Shimazu, Daiki Wada, Shuhei Maruyama, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study
Qinyue Zheng, Chunbing Bao, Yunpeng Ji, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Antiviral therapy of coronavirus disease 2019 (COVID-19)
Pao-Yu Chen, Jann‐Tay Wang, Shan‐Chwen Chang
Journal of the Formosan Medical Association (2023) Vol. 123, pp. S47-S54
Open Access | Times Cited: 4
COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023
Serap Şimşek Yavuz
Infectious Diseases and Clinical Microbiology (2023) Vol. 5, Iss. 3, pp. 165-187
Open Access | Times Cited: 2
Alterations of SARS-CoV-2 Evolutionary Dynamics by Pharmaceutical Factors
Matthew Halma
Infectious Diseases & Immunity (2024) Vol. 4, Iss. 1, pp. 35-40
Open Access
In Vitro Characterization of Inhibition Function of Calcifediol to the Protease Activity of SARS‐COV‐2 PLpro
Junjie Chen, Yaya Zhang, Bingchang Zhang, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 11
Closed Access
Intra-host variability of SARS-CoV-2: Patterns, causes and impact on COVID-19
Leandro R. Jones
Virology (2024) Vol. 603, pp. 110366-110366
Closed Access
Safety of Nirmatrelvir-Ritonavir Administration in Children With Immunodeficiency and/or Comorbidities With SARS-CoV-2 Infection: A Retrospective Clinical Report
Stefania Bernardi, Marco Roversi, Antonio Torelli, et al.
The Pediatric Infectious Disease Journal (2024)
Closed Access
Rapid screening methods for universal binding peptide aptamers against SARS-CoV-2 variant spikes, including omicron variants, and their application to diagnostic and therapeutic agents.
Nakanobu Hayashi
Research Square (Research Square) (2023)
Closed Access
Rapid screening methods for universal binding peptide aptamers against SARS-CoV-2 variant spikes, including omicron variants, and their application to diagnostic and therapeutic agents.
Nakanobu Hayashi, Chikako Abe, Jiro Kikuchi, et al.
Research Square (Research Square) (2023)
Closed Access
Spatial and Temporal Analysis of SARS-CoV-2 Genome Evolutionary Patterns
Shubhangi Gupta, Deepanshu Gupta, Sonika Bhatnagar
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases
R. Leonard, Rao Vn, Alexandria Bartlett, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access
Page 1

Scroll to top